Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCPS | Q96C86 | 11/20 | 0.58 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.56 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.56 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.56 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.56 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.56 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.56 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.56 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | DHFR | P00374 | 10/20 | 0.54 |
| ▸ | HTR1B | P28222 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15284417 | 0.85 | CSNK1A1 (0.74) | DCPSCSNK1A1CSNK1DPRKCDPAK1 | |
| SCHEMBL1154250 | 0.82 | CSNK1A1 (0.67) | DCPSCSNK1A1CSNK1DPRKCDPAK1 | |
| SCHEMBL1154579 | 0.82 | DCPS (0.68) | DCPSCSNK1A1CSNK1DPRKCDPAK1 | |
| SCHEMBL16863977 | 0.80 | DCPS (0.63) | DCPSCSNK1A1CSNK1DPRKCDPAK1 | |
| SCHEMBL8294968 | 0.80 | DCPS (0.69) | DCPSCSNK1A1CSNK1DPRKCDPAK1 | |
| SCHEMBL15283825 | 0.80 | DCPS (0.62) | DCPSCSNK1A1CSNK1DPRKCDPAK1 | |
| SCHEMBL1154216 | 0.77 | DCPS (0.75) | DCPSCSNK1A1CSNK1DPRKCDPAK1 | |
| SCHEMBL1154255 | 0.76 | DCPS (0.59) | DCPSCSNK1A1CSNK1DPRKCDPAK1 | |
| SCHEMBL15295903 | 0.76 | KCNH2 (0.67) | DCPSCSNK1A1CSNK1DPRKCDPAK1 | |
| SCHEMBL1154426 | 0.75 | DCPS (0.61) | DCPSCSNK1A1CSNK1DPRKCDPAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1014953-B1 | FORMULATIONS FOR HYDROPHOBIC PHARMACEUTICAL AGENTS | SUGEN INC (US) | 2012-04-25 | — | — | EP | disclosed |
| US-6911446-B2 | Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds | SUGEN, INC. (US) | 2005-06-28 | — | — | US | disclosed |
| US-6696482-B2 | QUINAZOLINE, NITROTHIAZOLE AND INDOLINONE BASED HYDROPHOBIC FORMULATIONS FOR ORAL ADMINISTRATION FOR TREATING CELL PROLIFERATION DISORDER IN A MAMMAL | SUGEN, INC. | 2004-02-24 | — | — | US | disclosed |
| US-20010014679-A1 | Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds | TANG PENG C (US) | 2001-08-16 | — | — | US | disclosed |
| US-20010012844-A1 | Formulations for hydrophobic pharmaceutical agents | SHENOY NARMADA (US) | 2001-08-09 | — | — | US | disclosed |
| US-6248771-B1 | MIXTURE CONTAINING SURFACTANT; ANTIPROLIFERATIVE AGENTS; KINASE INHIBITOR | SUGEN, INC. | 2001-06-19 | — | — | US | disclosed |
| US-6204267-B1 | Methods of modulating serine/thereonine protein kinase function with quinazoline-based compounds | SUGEN, INC. | 2001-03-20 | — | — | US | disclosed |
| EP-1014953-A2 | FORMULATIONS FOR HYDROPHOBIC PHARMACEUTICAL AGENTS | Sugen, Inc. (US) | 2000-07-05 | — | — | EP | disclosed |
| EP-0981519-A1 | METHODS OF MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION WITH QUINAZOLINE-BASED COMPOUNDS | Sugen, Inc. (US) | 2000-03-01 | — | — | EP | disclosed |
| WO-1998050370-A1 | METHODS OF MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION WITH QUINAZOLINE-BASED COMPOUNDS | SUGEN, INC. (US) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998038984-A2 | FORMULATIONS FOR HYDROPHOBIC PHARMACEUTICAL AGENTS | SUGEN, INC. (US) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010012844-A1 | Formulations for hydrophobic pharmaceutical agents | ABCG2, SLC7A5, SLCO4C1 | DCPS 4329/4885CSNK1A1 1868/4885CSNK1D 1722/4885 |
| US-20010014679-A1 | Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds | RAF1, STK3, MKNK1 | DCPS 3645/4885CSNK1A1 186/4885CSNK1D 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.